CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

about

Aptamer Therapeutics in Cancer: Current and Future.Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma.Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles.

P2860

Q52347485-99AF2C28-91D4-4215-8D58-C608D7D125CA Q55091606-1A97C741-516D-4735-A7D1-E98BCC64350E Q55265367-EEE4003A-5F40-4482-8604-5FFE30415122

P2860

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Item

http://www.wikidata.org/entity/Q48188365

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@en

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@nl

type

Item

label

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@en

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@nl

prefLabel

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@en

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@nl

P1476

CXCL12 and CXCR7 are relevant ...... esistance in multiple myeloma.

@en

P2093

Abdel K Azab

http://www.w3.org/2001/XMLSchema#string

Anna Simon

http://www.w3.org/2001/XMLSchema#string

Dagmar Wider

http://www.w3.org/2001/XMLSchema#string

Gabriele Ihorst

http://www.w3.org/2001/XMLSchema#string

Joschka Lorenz

http://www.w3.org/2001/XMLSchema#string

Justus Duyster

http://www.w3.org/2001/XMLSchema#string

Manik Chatterjee

http://www.w3.org/2001/XMLSchema#string

Monika Engelhardt

http://www.w3.org/2001/XMLSchema#string

Ralph Wäsch

http://www.w3.org/2001/XMLSchema#string

Sarah Decker

http://www.w3.org/2001/XMLSchema#string

P2860

A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma.

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Robust isolation of malignant plasma cells in multiple myeloma.

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro.

Myelomagenesis: capturing early microenvironment changes

Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model.

P304

36-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14807

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

Marie Follo

Johannes Moritz Waldschmidt

P577

2017-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28670693

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

about

P2860

P2860

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921